According to @StockMKTNewz, citing Bloomberg, Elon Musk’s Neuralink plans to start a US clinical trial in October to test a brain-computer interface that translates thoughts into text, creating a time-specific catalyst for headline risk monitoring. Source: Bloomberg via @StockMKTNewz. Neuralink previously disclosed it received FDA approval to begin its first in-human IDE study in 2023 and later announced its first human implant under the PRIME study in early 2024, framing the regulatory and technical backdrop for the upcoming trial. Source: Neuralink company announcements; FDA IDE framework. For traders, AI and neurotech headlines have historically coincided with higher volatility in AI-exposed equities and select AI-themed crypto assets, making the October window relevant for sentiment tracking and event-driven strategies. Source: Kaiko Research (2023) on AI token and equity correlation.